Program Guide – ASCO Meeting Program Guide
Rusfertide is a novel therapeutic option for patients with polycythemia vera. Many patients with ET are phlebotomy dependent to reduce of thrombosis risk. Rusfertide is exciting because it is a hepcidin memetic that can lower the hematocrit without effects on other blood counts and without causing iron deficiency. #ASCO22 #MPNs